Peptides

Glepaglutide

An investigational GLP-2 analogue for short bowel syndrome, with phase 3 evidence on dependence on intravenous support.

Phase 3 clinical evidence; investigational development

Glepaglutide molecular structure — Structure reference · C197H325N53O55

Practical use

Reviewed practical notes

Match the condition: Short bowel syndrome with intestinal failure is a specific clinical diagnosis.
Check the target: GLP-2 activity is not the same as GLP-1 activity.
Keep support changes clinical: A research endpoint is not an instruction to reduce prescribed intravenous nutrition or fluids.

EASE-1 phase 3 publication

Zealand current development and approval statement

Linked 2025 corrigendum record

Overview

Glepaglutide is a long-acting glucagon-like peptide-2 analogue being studied to improve intestinal absorption in short bowel syndrome with intestinal failure. GLP-2 and the GLP-1 target used by many weight-management medicines are different. This research concerns severe loss of intestinal function.

Risks and limitations

Participants required carefully managed parenteral support, meaning fluid or nutrition delivered intravenously. A trial description of tolerability is not a complete safety assessment, and reducing that support requires clinical management rather than self-directed changes.

How to read this

Zealand’s current program page describes glepaglutide as investigational and not approved for short bowel syndrome by the FDA or another health authority. It reports that recruitment for a second pivotal trial began in January 2026. That is development status, not authorization for routine treatment.

Research explained

EASE-1 randomized phase 3 trial

Who was studied

106 adults with short bowel syndrome and intestinal failure randomized and treated in a 24-week placebo-controlled trial.

What was found

One active treatment condition reduced weekly parenteral-support volume more than placebo. The other active condition did not achieve a statistically significant primary comparison.

What it cannot establish

This is an intestinal-failure endpoint, not evidence for routine digestive complaints. A published corrigendum is indexed; its full text was not available in this review. Detailed numerical tables are therefore not reproduced here.

Read the original study

Current development remains separate from a positive result

The sponsor’s current page independently reports the favorable EASE-1 primary comparison and describes another pivotal study. A promising trial does not make the candidate an approved substitute for established clinical care.

Supporting source

Correction history remains visible

The phase 3 publication has a linked corrigendum. The correction record is retained here so readers can check the corrected publication before relying on detailed estimates.

Supporting source